Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 10/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.50 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.49 |
| ▸ | PTPRC | P08575 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | RORB | Q92753 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3916316 | 0.82 | PTPN1 (0.55) | PTPN1PTGDR2PTPN2PTPRCKMT2A | |
| SCHEMBL4553644 | 0.78 | ALDH1A1 (0.56) | PTPN1ALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL3908023 | 0.77 | PTPN1 (0.52) | PTPN1ALDH1A1MEN1KMT2ARORC | |
| SCHEMBL3912034 | 0.74 | ALAD (0.40) | PTPN1PTPN2PTPRCKDM4E | |
| SCHEMBL3906538 | 0.74 | PTPN1 (0.60) | PTPN1PTGDR2PTPN2PTPRCMEN1 | |
| SCHEMBL12147393 | 0.71 | PTGDR2 (0.72) | PTGDR2 | |
| SCHEMBL3903861 | 0.71 | PTPN1 (0.53) | PTPN1PTPN2PTPRC | |
| SCHEMBL5989228 | 0.71 | PTGDR2 (0.50) | PTPN1PTGDR2PTPN6PTPN2PTPRC | |
| SCHEMBL4553643 | 0.70 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL12466271 | 0.70 | ADORA1 (0.49) | ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521473-B2 | Inhibitors of protein tyrosine phosphatase 1B | WYETH (US) | 2009-04-21 | — | — | US | disclosed |
| US-20050203087-A1 | Inhibitors of protein tyrosine phosphatase 1B | WYETH | 2005-09-15 | — | — | US | disclosed |
| WO-2005081954-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B | WYETH (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203087-A1 | Inhibitors of protein tyrosine phosphatase 1B | PTPRO, PTPRS, PTPRM | PTPN1 11/4885PTGDR2 3735/4885PTPN6 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.